DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT05492305

Unknown

Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health

Effect of Glucagon-like Peptide 1 (GLP1) Receptor Agonists on Mental Health in Patients With Obesity and Type 2 Diabetes (T2D): a Mixed Methods Study

Assets

Dulaglutide / GLP-1 / incretin class catch-all / Liraglutide / Semaglutide

Listed sites

1

Recruiting sites

1

Enrollment

20

estimated

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Subjective effect of GLP1 receptor agonist on mental health

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05492305
Org study ID314639

Timeline

Milestones

Study first posted2022-08-08actual
Last update posted2022-09-26actual
Study start2022-09estimated (month precision)
Primary completion2023-06estimated (month precision)
Study completion2023-08estimated (month precision)

Assets

Investigational agents

DulaglutideGLP-1 / incretin class catch-allLiraglutideSemaglutide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Patients being commenced on GLP1 receptor agonist for management of either for obesity or type 2 diabetes, according to the NICE guidelines for these indications.

Inclusion criteria

•being commenced on a glucagon-like peptide 1 (GLP1) receptor agonist for management of either for obesity or type 2 diabetes
•least 18 years of age
•able to consent, speak and read in fluent English.

Exclusion criteria

•not able to consent, speak and read in fluent English

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Patient-reported / QoL
6
Other clinical outcomes
1

Patient-reported / QoL

6 endpoints
Primary/protocol endpoint

subjective effect of GLP1 receptor agonist on mental health

Time frame:12-16 weeks

descriptive

Secondary/protocol endpoint

subjective effect of GLP1 receptor agonist on general wellbeing

Time frame:12-16 weeks

descriptive

Secondary/protocol endpoint

subjective effect of GLP1 receptor agonist on eating behaviours

Time frame:12-16 weeks

descriptive

Secondary/protocol endpoint

mean change in patient health questionnaire 9 (PHQ9) score with GLP1 receptor agonist over 12-16 weeks

Time frame:12-16 weeks

change from baseline, improvement

Secondary/protocol endpoint

mean change in generalised anxiety disorder assessment (GAD) score with GLP1 receptor agonist over 12-16 weeks

Time frame:12-16 weeks

change from baseline, improvement

Secondary/protocol endpoint

mean change in eating disorder examination questionnaire (EDE-Q) score with GLP1 receptor agonist over 12-16 weeks

Time frame:12-16 weeks

change from baseline, improvement

Other clinical outcomes

1 endpoint
Secondary/protocol endpoint

subjective effect of GLP1 receptor agonist on binge eating, if present

Time frame:12-16 weeks

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.